[en] PET is a diagnostic method that creates high resolution, 3 dimensional tomographic images of the distribution of positron emitting radionuclides in the human body. Recent technological developments allow the use of whole-body PET devices in clinical oncology. 18FDG is a glucose analog transported and competitively used with glucose reflecting the increased glucose metabolism into malignant cells. Differential diagnosis between chronic pancreatitis and pancreatic cancer is already a well-documented indication. For initial staging of gastro-esophageal and colorectal tumours, results are preliminary but the clinical impact seems to be rather limited. At present, the major indication of FDG-PET is the detection and staging of colorectal cancer recurrences. FDG-PET allows the differentiation between scared tissue and tumour when structural imaging is often confusing. In the same time, the whole-body imaging capability provides unique information that can modify loco-regional and liver staging. Overall, FDG-PET affects the clinical management of 30 to 40% of these patients. Quantitative assessment of therapeutic response to chemotherapy regimen appears to be one of the most promising applications of FDG-PET. Since the most effective therapy of colorectal cancer are often surgical, the role of chemotherapy in colorectal cancer remains limited to adjuvant therapy and in advanced disease. However, FDG-PET could be of great value in assessing the response of oesophageal carcinomas to chemo-radio therapy, before surgery. In our experience, FDG-PET appears to be the first line diagnostic method in the detection and staging of colorectal recurrence and differential diagnosis of pancreatic tumour versus chronic pancreatitis.
Disciplines :
Oncology
Author, co-author :
Paulus, P.
Hustinx, Roland ; Université de Liège - ULiège > Département des sciences cliniques > Médecine nucléaire
Daenen, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Médecine nucléaire
Comhair, Nicole ; Centre Hospitalier Universitaire de Liège - CHU > Administration des patients - Expédition
Rigo, Pierre ; Université de Liège - ULiège > Département des sciences de la motricité > Pathologie générale et médecine nucléaire
Language :
English
Title :
Usefulness of 18fdg Positron Emission Tomography in Detection and Follow-up of Digestive Cancers
Gallagher, B.M., Fowler, J.S., Gutterson, N.I., Metabolic trapping as a principle of radiopharmaceutical design : Some factors responsible for the biodistribution of F-18-2-deoxy-2-fluoro-D-glucose (1989) J Nucl Med, 19, pp. 1154-1161
Sokoloff, L., Reivich, M., Kennedy, C., The (14C)-deoxyglucose method for the measurement of local cerebral glucose utilization : Theory, procedure and normal values on the conscious and anesthetized albino rat (1977) J Neurochem, 28, pp. 897-916
Bares, R., Klever, P., Hauptmann, S., F-18 Fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer (1994) Radiology, 192, pp. 79-86
Friess, H., Langhans, J., Ebert, M., Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (1995) Gut, 365, pp. 771-777
Inokuma, T., Tamaki, N., Torizuka, T., Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose : Comparison with CT and US (1995) Radiology, 195, pp. 345-352
Falk, P.M., Gupta, N.C., Thorson, A.G., Positron emission tomography for preoperative staging of colorectal carcinoma (1994) Dis Colon Rectum, 37, pp. 153-156
Gupta, N.C., Falk, P.M., Frank, A.L., Pre-operative staging of colorectal carcinoma using positron emission tomography (1993) Nebraska Med J, pp. 30-35
Torizuka, T., Tamaki, N., Inokuma, T., In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET (1995) J Nucl Med, 36, pp. 1811-1817
Larson, S.M., Cohen, A.M., Cascade, M.B.A., Clinical application and economic implications of PET in the assessment of colorectal cancer recurrence . A retrospective study Abstract from the 1994 ICP Meeting, , Institute for clinical PET, Fairfax, Virginia
Pounds, T.R., Valk, P.E., Haseman, M.K., Whole-body PET-FDG imaging in diagnosis of recurrent colorectal cancer (1995) J Nucl Med, 36, 57p
Schiefers, C., Penninckx, F., De Vadder, N., Contribution of PET in the diagnosis of recurrent colorectal cancer : Comparison with conventional imaging (1995) Eur J Surg Oncol, 21, pp. 517-522
Beets, G., Penninckx, F., Schiepers, C., Clinical value of whole-body positron emission tomography with 18F-fluorodeoxyglucose in recurrent colorectal cancer (1994) Br J Surg, 81, pp. 1666-1671
Daenen, F., Hustinx, R., Paulus, P., Detection of recurrent colorectal carcinoma with whole-body FDG PET (1996) J Nucl Med, 37, p. 261
Shields, A.T., Graham, M.M., Helton, S., Utility F-18 FDG PET in preoperative evaluation of patients with colon carcinoma metastatic to liver (1995) J Nucl Med, 36, p. 106
Vitola, V., Delbeke, D., Martin, P., Positron Emission Tomography to stage suspected metastatic colorectal carcinoma to the liver (1996) AJ Surg, 171, pp. 21-26